Vanda Pinto, PhD, science writer —

Ultomiris (ravulizumab) was shown to efficiently manage atypical hemolytic uremic syndrome (aHUS) in a woman in her 30s who had received Soliris (eculizumab) for more than a decade following a kidney transplant, according to a recent case study. Researchers noted there had previously been only a single…

COVID-19 might have triggered a relapse of atypical hemolytic uremic syndrome (aHUS) in a 36-year-old woman, according to a recent case report. Despite treatment with Soliris (eculizumab), the patient ultimately died. However, a literature review conducted by study authors revealed nine other cases of COVID-19-associated aHUS and showed…

An 11-year-old boy with atypical hemolytic uremic syndrome (aHUS) became severely ill following infection with SARS-CoV-2, the virus that causes COVID-19, according to a recent case report. “Our study [shows] that severe SARS-COV-2 infection can be developed in pediatric patients with co-existing [aHUS],” the author wrote. The report, “…

A newly identified mutation in the TSEN2 gene that causes craniofacial abnormalities, intellectual and developmental disabilities, as well as atypical hemolytic uremic syndrome (aHUS), was found in six children, a genetic study shows. Based on these observations, scientists proposed naming the new syndrome “TRACK” which stands for TSEN2-related atypical…

By shortening the time spent on treatment, Ultomiris (ravulizumab), an approved therapy for atypical hemolytic uremic syndrome (aHUS), may be more effective at reducing lost productivity costs compared with its predecessor Soliris (eculizumab), according to a new study. The study, “Quantifying the economic effects of ravulizumab…

If closely monitored, women with atypical hemolytic uremic syndrome (aHUS) can have successful and uncomplicated pregnancies, including those on dialysis or patients who had undergone a kidney transplant, according to a new study. Additionally, researchers confirmed that patients can safely and effectively be treated with Soliris (eculizumab), an…

COVID-19 appears to have triggered an exaggerated immune response in a toddler, leading to the development of atypical hemolytic uremic syndrome (aHUS) in the absence of disease-relevant mutations, scientists reported. “This is a rare case report of a child with COVID-19 developing HUS. Since HUS developed following a COVID-19…

The case of a woman with unusual symptoms for atypical hemolytic uremic syndrome (aHUS) — including normal hemoglobin levels and mildly low platelet counts — highlights the need for better and more clear diagnostic criteria for this condition, according to researchers. The goal is to ensure that patients can…